Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors.

Autor: Bear AS; Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine., Nadler RB; The College of Arts and Sciences., O'Hara MH; Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine.; Abramson Cancer Center, and., Stanton KL; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Xu C; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Saporito RJ; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Rech AJ; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Baroja ML; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Blanchard T; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Elliott MH; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Ford MJ; MSBioworks, Ann Arbor, Michigan, USA., Jones R; MSBioworks, Ann Arbor, Michigan, USA., Patel S; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Brennan A; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., O'Neil Z; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Powell DJ Jr; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Department of Pathology and Laboratory Medicine and., Vonderheide RH; Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine.; Abramson Cancer Center, and.; Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Linette GP; Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine.; Abramson Cancer Center, and.; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Carreno BM; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Department of Pathology and Laboratory Medicine and.; Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2024 Sep 17; Vol. 134 (21). Date of Electronic Publication: 2024 Sep 17.